Learn how Twist Bioscience technology can advance your cell therapy research and development. Twist’s synthetic antibody and T cell receptor (TCR) discovery libraries are built using our proprietary oligo synthesis technology, ensuring complexity, diversity, and quality. These libraries include highly diverse synthetic naïve scFv and VHH antibody phage display libraries for discovery of targeting domains for CAR-T constructs as well as combinatorically assembled TCR libraries from gene fragments. In this webinar, Twist Bioscience’s CSO Aaron Sato will present several proof-of-concept studies showing how these technologies can be utilized for cell therapies.  

GPCRs are ubiquitous in human biology, participating in diverse processes such as metabolism, inflammation, neurotransmission, and carcinogenesis. The Twist GPCR Library Series leverages all known GPCR-ligand interactions and existing GPCR antibody diversities to enable antibody discovery beyond existing GPCR-targeting small molecules and antibodies, which cover only 13% of the human GPCRome. This fully human synthetic library series includes the GPCR 2.0 scFv, GPCR 3.0 scFv, and VHH hShuffle GPCR libraries.

Using Twist’s high-throughput DNA synthesis platform, multiple high diversity synthetic antibody libraries have been built to serve as powerful tools for antibody discovery. Leveraging these highly diverse libraries, we have been able to identify high-affinity antibody candidates for a variety of targets. Here we demonstrate the antibody discovery process for 6 cytokine or immunomodulatory protein targets. This process spans constructing synthetic antibody libraries, using phage display to pan libraries against biotinylated protein targets, and screening for lead candidates through ELISA binding assays and NGS enrichment tracking. Utilizing a high-throughput approach, candidates are reformatted into full length IgG or VHH-Fc; the resulting monoclonal antibodies are then validated through SPR and cell-based assays. Many high affinity candidates with ranges of picomolar to nanomolar binding were identified for the six targets, demonstrating the efficacy of this discovery process.